Dartmouth's Lung Biology Center is a premier hub for high-impact research that yields life-changing results. Its contributions to the understanding and treatment of cystic fibrosis and other lung diseases include the discovery of new drugs, breakthroughs in the battle against infections, and the transformation of care of patients with cystic fibrosis across the country.
Your support for the Lung Biology Center will provide the sustaining and flexible funding needed to fuel such discoveries and translate them rapidly into patient care and disease prevention.
Goal: $10 million
Through the following philanthropic investments, Dartmouth’s Lung Biology Center will accelerate the pace of discovery and the translation of those discoveries into personalized, highly effective therapies for patients with chronic lung diseases:
- Catalyze the growth of high-potential, groundbreaking research. An infusion of current-use gifts and an endowed innovation fund will provide the resources needed to grow new high-potential lines of research. Areas of investment include deep-sequencing genetic and microbiome studies and potential stem cell therapies. ($3.5 million)
- Attract and retain the most innovative faculty. Endowed support provides faculty with the time and freedom to conduct more high-risk–high-reward research that departs from the “safe bets” typically supported by traditional and short-term extramural sources. New professorships and faculty fellowships will ensure that Dartmouth’s Lung Biology Center can continue to attract and retain the best, most collaborative investigators. ($6 million)
- Enhance learning opportunities for Dartmouth students. Serving as teacher-scholars, Lung Biology faculty welcome dozens of graduate and undergraduate students into their labs as research partners, helping to prepare them for roles as future leaders in science and medicine. Faculty often remark on the energy, creativity, and commitment that Dartmouth students bring to their teams. ($500,000)
Could there be a connection between chronic inflammatory lung diseases, such as pulmonary fibrosis, and chronic autoimmune diseases, such as rheumatoid arthritis? That’s one of the important questions that Dr. Richard Enelow, a professor of medicine and of microbiology and immunology at the Geisel School of Medicine and a pulmonologist at Dartmouth-Hitchcock, is exploring in his research laboratory.